EGFR and lung cancer: What is the central nervous system (CNS) activity of lazertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), in patients with EGFR-variant non–small cell lung cancer (NSCLC) who have brain metastases after unsuccessful treatment with first-generation or second-generation EGFR TKIs?